Sales of Healthcare Services segment has gone up 10.06% to Rs 1,542.25 crore (accounting for 53.69% of total sales).  Sales of Clinics segment rose 25.81% to Rs 210.51 crore (accounting for 7.33% of total sales).  Sales of others segment has gone down 1.82% to Rs 1.08 crore (accounting for 0.04% of total sales).  Inter-segment sales came down from Rs 5.75 crore to Rs 4.62 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 26.43% to Rs 273.36 crore.  PBIT of Healthcare Services segment rose 57.08% to Rs 216.40 crore (accounting for 79.16% of total PBIT).  PBIT of Clinics reported profit of Rs 7.74 crore compared to loss of Rs 6.61 crore.  PBIT of others segment rose 22.86% to Rs -0.86 crore (accounting for -0.31% of total PBIT).  

PBIT margin of Healthcare Services segment rose from 9.83% to 14.03%.  PBIT margin of Clinics segment rose from negative 3.95% to 3.68%.  PBIT margin of others segment fell from negative 63.64% to negative 79.63%.  Overall PBIT margin rose from 7.38% to 9.52%.  

Operating profit margin has jumped from 13.01% to 14.36%, leading to 8.36% rise in operating profit to Rs 411.83 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 15.02% to 15.86%.   Purchase of finished goods cost rose from 35.56% to 35.60%.   Employee cost decreased from 16.19% to 13.54%.   Other expenses rose from 20.29% to 20.66%.   

Other income rose 417.72% to Rs 20.45 crore.  Provision for interest fell 27.12% to Rs 98.56 crore.  Loan funds declined from Rs 3,279.47 crore as of 31 March 2020 to Rs 2,494.72 crore as of 31 March 2021.  Inventories declined from Rs 737.83 crore as of 31 March 2020 to Rs 249.48 crore as of 31 March 2021.  Sundry debtors were higher at Rs 1,331.17 crore as of 31 March 2021 compared to Rs 1,027.24 crore as of 31 March 2020.  Cash and bank balance rose to Rs 724.40 crore as of 31 March 2021 from Rs 466.75 crore as of 31 March 2020.  Investments rose to Rs 1,342.56 crore as of 31 March 2021 from Rs 434.01 crore as of 31 March 2020 .  

Provision for depreciation fell 15.49% to Rs 138.48 crore.  Fixed assets declined from Rs 7,321.60 crore as of 31 March 2020 to Rs 6,550.92 crore as of 31 March 2021.  Intangible assets increased from Rs 346.21 crore to Rs 461.27 crore.  

Profit before tax grew 129.88% to Rs 195.24 crore.  Share of profit/loss was 4,075.61% higher at Rs 17.12 crore.  Extraordinary items were decreased to Rs 25.20 crore.  Provision for tax was expense of Rs 67.67 crore, compared to Rs 74.04 crore.  Effective tax rate was 28.49% compared to 26.10%.

Net profit attributable to owners of the company decreased 23.48% to Rs 167.85 crore.  

Equity capital increased from Rs 69.56 crore as of 31 March 2020 to Rs 71.89 crore as of 31 March 2021.  Per share face Value remained same at Rs 5.00.  

Promoters' stake was 29.82% as of 31 March 2021 ,compared to 30.81% as of 31 March 2020 .  Promoters pledged stake was 27.94% as of 31 March 2021 ,compared to 36.66% as of 31 March 2020 .  

Full year results analysis.

Consolidate net sales (including other operating income) of Apollo Hospitals Enterprise has declined 6.11% to Rs 10560.01 crore.  Sales of Healthcare Services segment has gone down 12.65% to Rs 5,023.02 crore (accounting for 47.45% of total sales).  Sales of Retail Pharmacy segment has gone down 52.91% to Rs 2,269.84 crore (accounting for 21.44% of total sales).  Sales of Clinics segment fell 2.09% to Rs 681.78 crore (accounting for 6.44% of total sales).  Sales of others segment has gone down 4.35% to Rs 4.18 crore (accounting for 0.04% of total sales).  Inter-segment sales rose Rs 24.94 crore to Rs 25.01 crore.  

Profit before interest, tax and other unallocable items (PBIT) has slumped 41.68% to Rs 564.28 crore.  PBIT of Healthcare Services segment fell 59.03% to Rs 287.77 crore (accounting for 51.00% of total PBIT).  PBIT of Retail Pharmacy segment fell 48.56% to Rs 149.26 crore (accounting for 26.45% of total PBIT).  PBIT of Clinics segment fell 51.10% to Rs -10.69 crore (accounting for -1.89% of total PBIT).  PBIT of others segment rose 2.86% to Rs -3.24 crore (accounting for -0.57% of total PBIT).  

PBIT margin of Healthcare Services segment fell from 12.22% to 5.73%.  PBIT margin of Retail Pharmacy segment rose from 6.02% to 6.58%.  PBIT margin of Clinics segment rose from negative 3.14% to negative 1.57%.  PBIT margin of others segment fell from negative 72.08% to negative 77.51%.  Overall PBIT margin fell from 8.58% to 5.33%.  

Operating profit margin has slumped from 14.11% to 10.77%, leading to 28.34% decline in operating profit to Rs 1,137.41 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.93% to 15.19%.   Purchase of finished goods cost rose from 33.44% to 39.18%.   Employee cost decreased from 16.32% to 14.98%.   Other expenses fell from 20.33% to 20.00%.   

Other income rose 66.81% to Rs 44.99 crore.  Provision for interest fell 15.68% to Rs 449.22 crore.  Loan funds declined from Rs 3,279.47 crore as of 31 March 2020 to Rs 2,494.72 crore as of 31 March 2021.  Inventories declined from Rs 737.83 crore as of 31 March 2020 to Rs 249.48 crore as of 31 March 2021.  Sundry debtors were higher at Rs 1,331.17 crore as of 31 March 2021 compared to Rs 1,027.24 crore as of 31 March 2020.  Cash and bank balance rose to Rs 724.40 crore as of 31 March 2021 from Rs 466.75 crore as of 31 March 2020.  Investments rose to Rs 1,342.56 crore as of 31 March 2021 from Rs 434.01 crore as of 31 March 2020 .  

Provision for depreciation fell 7.51% to Rs 573.13 crore.  Fixed assets declined from Rs 7,321.60 crore as of 31 March 2020 to Rs 6,550.92 crore as of 31 March 2021.  Intangible assets increased from Rs 346.21 crore to Rs 461.27 crore.  

Profit before tax shrink 65.34% to Rs 160.05 crore.  Extraordinary items were decreased to Rs 60.65 crore.  Provision for tax was expense of Rs 84.7 crore, compared to Rs 225.19 crore.  Effective tax rate was 38.24% compared to 34.28%.

Minority interest increased 41.27% to Rs -13.59 crore.  Net profit attributable to owners of the company decreased 66.95% to Rs 150.36 crore.  

Equity capital increased from Rs 69.56 crore as of 31 March 2020 to Rs 71.89 crore as of 31 March 2021.  Per share face Value remained same at Rs 5.00.  

Promoters' stake was 29.82% as of 31 March 2021 ,compared to 30.81% as of 31 March 2020 .  Promoters pledged stake was 27.94% as of 31 March 2021 ,compared to 36.66% as of 31 March 2020 .  

Cash flow from operating activities decreased to Rs 1,273.48 crore for year ended March 2021 from Rs 1,292.84 crore for year ended March 2020.  Cash flow used in acquiring fixed assets during the year ended March 2021 stood at Rs 295.49 crore, compared to Rs 512.98 crore during the year ended March 2020. 

Other Highlights

The Board recommended a dividend of Rs 3 per share (60% of face value of Rs 5 per share) for the financial year ended 31st March 2021.

Exceptional items represents- Impairment of the carrying value of investment of Rs 450 lakh held in an associate, Stemcyte Therapeutics India Private Limited and profit on sale of a nursing school of Rs 466 lakh earned by a subsidiary, Assam Hospitals Limited.

Company acquired 100% of the equity shares of Apollo HealthCo Limited. This acquisition may help the Company to accomplish the object of creating India's largest Omni channel healthcare platform.

Company is expected to retain dominant majority shareholding in Apollo HealthCo Limited.

In Q4FY21- occupancy in mature hospitals was at 3,365 beds (64% occupancy). New hospitals had an occupancy of 1,266 beds (60%) occupancy).

Inpatient Volumes across the group increased by 9% from 99,197 in Q4FY20 to 108,169 in Q4FY21.

Average Revenue Per Occupied bed, registered a growth of 11% in Q4FY21 as compared to the previous year same quarter.

Company has 71 hospitals with total bed capacity of 10,209 beds as of Mar 31 2021.

Company has launched one of the biggest standalone, state-of-the-art fertility centres in Banjara Hills, Hyderabad. The fertility centre is spread across 7,000 sq ft catering to all sorts of infertility related issues.

In FY21-Apollo Health and Lifestyle Limited (AHLL) reported EBITDA of `Rs 98 mil as compared to EBITDA of Rs 18 mil in FY20.

Management Commentary: Suneeta Reddy, Managing Director, said "Our digital and omni-channel play is a natural consequence of our long-held ideal of taking care closer to the consumer. Apollo Hospitals has a proven track record of incubating new business verticals and growing them both in size and profitability. We are always focused on creating and enhancing shareholder value, and we will ensure Apollo 24/7 delivers on its potential, with the separate focused management team we have put in place, who bring with them a deep understanding of healthcare, technology and digital perspectives."

Dr Prathap C Reddy, Founder Chairman, said "I started Apollo Hospitals to bring healthcare of international standards within the reach of every individual. Our new digital approach will allow us to serve most Indians, wherever they are, while maintaining the high standard and continuum of clinical care that consumers rightly expect from us. Now I believe we in India, have the capability and are poised to become the health provider to the World, through a Doctor-Led, Digital —First approach".